^
Association details:
| Biomarker: | CLDN18.2 positive |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug Class: | CLDN18.2-targeted antibody-drug conjugate |
| Direction: | Sensitive |
Evidence:
Source:
Title:
332 / 7 - Development of a novel therapeutic CLDN18.2 monoclonal antibody and antibody drug conjugate for the treatment of CLDN18.2 positive cancers
Published date:
03/09/2022
Excerpt:
...we describe the preclinical development of a novel therapeutic CLDN18.2 mAb and ADC….Complete regression of CDX tumors was observed in response to treatment with the CLDN18.2-ADC in three separate CLDN18.2 positive models (two pancreas, one gastric).
